Clinical Trial Update: Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy and safety of remibrutinib (LOU064) in chronic urticaria, including chronic spontaneous urticaria and chroni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inducible Urticaria
• Spontaneous Urticaria
• Urticaria

Drugs mentioned

• Remibrutinib (LOU064) (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | Status: RECRUITING